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& therapy, and studies of the determinants of CMV-speciﬁc
immune recovery, are a priority for this patient population.
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Allogeneic hematopoietic stem cell transplant (HCT) is
a curative therapy for sickle cell disease (SCD). However,
majority of patients lack a matched sibling or unrelated
donor. The use of a partially matched related donor would
provide donors for majority of the patients. We report the
results of 8 consecutive pediatric patients with SCD who had
a prior stroke, who underwent a T cell depleted HLA-hap-
loidentical HCT using a reduced intensity conditioning
regimen without total body irradiaiton. The median age was
75 yrs (4-17) with the median follow up of 73 yrs (3-9).
The ﬁrst 3 patients received ﬂudarabine (150-200 mg/m2),
thiotepa (10mg/kg), targeted busulfan (900 ng/ml for 4 d),
rabbit antithymocyte globulin (rATG) (10mg/kg x 3 d), and
OKT3 (0.1mg/kgmaximum over d +1 to +20). The subsequent
5 patients received busulfan (900ng/ml x 4 d), thiotepa
(10mg/kg), cyclophosphamide (200 mg/kg) and OKT3
(0.1mg/kg max on d-10 to +17) as well as mycophenolate
mofetil for graft versus host (GVHD) prophylaxis. The
product consisted of a CD34+ selected product infused on d0
and a CD3+ depleted product infused on d+1. The infused
products had a mean total nucleated cell (TNC) of 450680 x
106 kg (10-1890), CD34+ cells of 25.416.3 x 106/kg (6-57)
and CD3+ cells of 0.070.07 x 106/kg (0.006-0.168). All 8
patients achieved donor engraftment with a median of 12
d (10-14). Donor engraftment was maintained in 5 patients,
with one patient requiring a second stem cell infusion. TheTable 1
Patients and donors characteristics
Patient
number
Age
(years)
Sex Donor
Age
(years)
Donor
Sex
Source of
Progenitor
Age
Dif
(ye
1 6 Male 62 Male PB 56
2 5 Male 60 Female PB 55
3 2.5 Female 45 Female BM 42.
4 5.5 Female 63 Male PB 57.
5 7 Male 75 Female PB 68
6 2 Female 60 Female PB 58
7 11 Male 69 Male PB 58
8 8.5 Female 68 Male PB 59.
9 9.5 Female 46 Female BM 36.
10 2 Male 48 Female BM 46
11 1 Male 74 Male PB 73
12 9 Male 62 Male PB 53
13 0.25 Female 71 Male PB 70.
PB: Peripheral Blood, BM: BoneMarrow, ALL: Acute Lymphoblastic Leukemia, TM: T
CD4 dif: CD4 deﬁciency, AML: Acute Myeloid Leukemia, MPS: Mucopolysaccharidomedian time to rejection for the 4 patients was 30 d (22-44)
after HSCT. Of the 5 engrafted patients, 4 patients developed
acute GVHD (3 with grade I-II and 1 with Grade III). Of the 5
engrafted patients, 3 developed chronic GVHD (1 with
limited and 2 with extensive). The 2 patients with extensive
GVHD died of complication of GVHD. The 3 surviving
patients have been transfusion independent with no
evidence of SCD related complications. Indices of hemolysis
decreased after HCT with decreased reticulocyte count, bili-
rubin and LDH. Themedian hemoglobin increased from9.6
0.6 to 13.6  2. Renal and cardiac were stable after HCT. MRI
showed no new infarct or vessel occlusion. In summary, 3
patients survived free of SCD, 2 engrafted but died of
complications from GVHD and 3 had recurrent SCD after
graft rejection. Despite good outcomes in 3 of the 8 patients,
rejection, chronic GVHD and transplant related mortality
were signiﬁcant problems. Recently, Bolaños-Meade et al.
published the result of haploidentical HCT for SCD using
post-transplant cyclophosphamide. Both regimens encoun-
tered graft failure, however GVHD and mortality was not as
prevalent as our report. Though limited, our data suggest
that for patients with SCD, graft-versus-host disease
prophylaxis after haploidentical HCT with high dose cyclo-
phosphamide may be a safer regimen and further studies are
warranted.
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Background: HLA matching is one of the most important
factors affecting patients' prognosis after hematopoietic
stem cell transplantation (HSCT). Currently when there are
no HLA-match siblings, transplantation centers try to ﬁnd
unrelated HLA-matched donor through bone marrow and
cord blood registries. However, few studies showed that
searching extended families such as parents, grandparents,
aunts and uncles for an appropriate donor is useful.
Methods: This is a retrospective study from our center in
which the patients who underwent HSCT of any diseases
and their grandparents were as donors included in the
study. The principal data including graft-versus-host-diseaseference
ars)
Disease Acute
GVHD
Chronic
GVHD
Patient Status
ALL Yes No Full chimerism/Alive
TM II Yes No Full chimerism/Alive
5 LAD I Yes Yes Full chimerism/Alive
5 FA Yes No Full chimerism/Alive
TM II Yes No Rejected/Dead
AML No No Rejected/Alive
FA No No Full chimerism/Alive
5 CD4 dif. Yes Yes Full chimerism/Alive
5 AML Yes No Rejected/Dead
MPS I Yes No Full chimerism/Alive
LAD I Yes Yes Full chimerism/Alive
TM III No No Rejected/Alive
75 SCID Yes No Full chimerism/Alive
halassemia Major, LAD: Leukocyte Adhesion Deﬁciency, FA: Fanconi Anemia,
ses, SCID: Severe Combined Immunodeﬁciency.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S342eS354S346(GVHD) occurrence, overall survival (OS) and disease free
survival (DFS) were used as main outcomes in these
transplantations.
Results: Thirteen patients including 7 boys and 6 girls with
mean age 5.33 years (range: 0.25-11) were detected through
the data registry bank. The mean donors' age was 61.77 years
(range: 45-75) and mean age difference was 56.44 years
(range: 36.5-73) [Table 1]. Regarding GVHD occurrence, 10
patients did experience acute GVHD [Table 1]. With median
follow-up of 16 months OS and DFS were 83% and 69%
respectively.
Conclusion: Although searching the extended family for
HLA-matched donors especially among grandparents seems
very uncommon, this can increase the chance of well-toler-
ated and success transplantation especially in regions where
consanguinity is common.
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Haploidentical donor is often the only source of graft for
most patients in developing countries due to lack of suitably
matched donors from international registries and the
prohibitive cost involved in the procurement process. We
conducted a pilot study with posttransplant cyclophospha-
mide and haploidentical PBSC graft. The donors selected
were either mother or NIMA mismatched siblings irre-
spective of NK cell alloreactivity. The conditioning protocol
was developed based on Johns Hopkins regimen of Fludar-
abine and low-dose Cyclophosphamide pre-transplant with
escalating doseMelphalan 70-140mg/m2 replacing 2 Gy TBI.
Post-transplant Cyclophosphamide was administered 72hrs
after infusion of the graft at 50 mg/kg twice at 24 hrs interval
followed by Cyclosporine and MMF.
8 patients (median age-16, 5-43) underwent Haplo-HCT; 5
patients with refractory AML had a median BM blast count of
50% (20-80%) having failed at least two lines of treatment.
Two patients had severe aplastic anemia and one had thal-
assemia. The ones with AML received high dose AraC and
mitoxantrone from day-14 to -12. The conditioning was
tolerated without any major non-hematological toxicity. The
median CD34 was 7.06 x 106/kg (range 5.05-11.06) and CD3
was 36 x 107/kg (range 8-79).
All patients engrafted with neutrophils > 500/ml on day +14
(range12-17) and platelet count > 20,000/ml on day +15
(range 9-38) with > 95% donor chimerism on day +30 with
morphological CR. None of the patients with leukemia
developed de-novo GVHD. Three relapsed between days
100-150 and two of them achieved a CR following a second
transplant from the same donor. Two patients in CR died of
multi-drug resistant gram-negative bacterial sepsis. All three
patients with non-malignant disease developed unexpected
alloreactivity. One patient with SAA developed severerefractory HLH on day +21 and the other a periengraftment
idiopathic pneumonitis. Both succumbed to their complica-
tions. Another patient with thalassemia developed severe
HLH on day 60 related to EBV, whilst on treatment for grade 3
acute GVHD. In multiply treated advanced leukemia, the
introduction of the PBSC graft without any immunosup-
pression for 72 hours probably allowed a strong GVL effect
and post-transplant cyclophosphamide was successful in
abrogating clinically signiﬁcant GVHD. In sharp contrast, all
the three patients with non-malignant disease experienced
early and unexpected alloreactivity with the same protocol.
We speculate that the lack of previous cytotoxic therapy
might have left them vulnerable to such alloreactivity
mediated by residual host APCs.
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Early relapse (within 120 days) of high risk acute leukemia
after any form of allogeneic HCT, augers a poor outcome. We
report our experience with 4 such patients who relapsed
within 120 days of undergoing a haploidentical PBSCTwith or
without posttransplant cyclophosphamide. None developed
GVHD even with prophylactic DLI. Three had relapsed
refractory AML at the time of the ﬁrst haploidentical HCT and
one was transplanted for high risk ALL. The marrow blast
count at the time of second transplant was 20-80%. The
patients were conditioned with Fludarabine or Cladribine
withmelphalan (70mg/m2) ororal busulfan (4mg/kg) anddid
not receive any GVHD prophylaxis. Cryopreserved PBSC graft
was infused with CD34+ cells varying between 2-3 x 106/kg.
All the patients engrafted within 14 days and all developed
grade 2-3 acute GVHD by day 10. GVHD was treated with
steroids and etanercept along with tacrolimus andMMF. One
patient succumbed early to multidrug resistant Klebsiella
sepsis on day 15. The BM on day 30 in the other 3 patients
showed 100 % donor chimerismwith MRD levels of less than
0.1% on ﬂow cytometry. At a short follow up of 90 days from
the second haploidentical HCT, two out of three patients are
alive in CR with tapering immunosuppresion and the other
was lost to follow up after 50 days. Our data shows that
a haploidentical graft can induce a potent enough GVL effect
to induce remission even in refractory leukemia. These ﬁnd-
ings highlight the fact that even if a patient with refractory
leukemia relapses early after an allogeneic HCT without
developing GVHD, they deserve a second graft from the same
donor with minimally toxic conditioning with the purpose of
inducing a GVHD/GVL effect.
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